Mutations in p53 result in the loss of the wild-type (WT) activity; however, these mutants exert either a ‘dominant-negative' effect on the p53 WT activity or a ‘gain-of-function' effects.1, 2, 3 Humans with a Li–Fraumeni syndrome, an autosomal-dominant disorder owing to germline mutations in p53 gene, are at an increased risk of tumorigenesis.4 Thus targeting p53 mutant offers a promising approach for cancer chemotherapeutics. This evidence concerns the gene TP53 and cancer.